OSI Systems, Inc. (OSIS) Touches $67.82 Formed H&S; Recro Pharma (REPH) Has 1.5 Sentiment

Recro Pharma, Inc. (NASDAQ:REPH) Logo

OSI Systems, Inc. (OSIS) formed inverse H&S with $70.53 target or 4.00% above today’s $67.82 share price. OSI Systems, Inc. (OSIS) has $1.29 billion valuation. The stock decreased 1.47% or $1.01 during the last trading session, reaching $67.82. About 88,871 shares traded. OSI Systems, Inc. (NASDAQ:OSIS) has declined 12.11% since April 20, 2017 and is downtrending. It has underperformed by 23.66% the S&P500.

Recro Pharma (REPH) investors sentiment decreased to 1.5 in 2017 Q4. It’s down -0.15, from 1.65 in 2017Q3. The ratio is negative, as 27 hedge funds increased or started new equity positions, while 18 reduced and sold their equity positions in Recro Pharma. The hedge funds in our database now have: 9.57 million shares, down from 9.63 million shares in 2017Q3. Also, the number of hedge funds holding Recro Pharma in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 14 Increased: 20 New Position: 7.

Since January 1, 0001, it had 0 insider buys, and 7 sales for $3.53 million activity.

Ratings analysis reveals 100% of Recro Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Recro Pharma, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $12.0 while the high is $21.0. The stock’s average target of $16.50 is 43.48% above today’s ($11.5) share price. REPH was included in 3 notes of analysts from September 16, 2016. The firm has “Buy” rating by Roth Capital given on Friday, September 16. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by Aegis Capital on Monday, November 14. The firm has “Overweight” rating by Piper Jaffray given on Monday, December 19.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 earnings per share, down 61.90% or $0.26 from last year’s $-0.42 per share. After $-0.63 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94% negative EPS growth.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $224.24 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

The stock increased 0.44% or $0.05 during the last trading session, reaching $11.5. About 162,935 shares traded. Recro Pharma, Inc. (REPH) has risen 37.47% since April 20, 2017 and is uptrending. It has outperformed by 25.92% the S&P500.

Broadfin Capital Llc holds 3.68% of its portfolio in Recro Pharma, Inc. for 2.44 million shares. Lyon Street Capital Llc owns 363,495 shares or 1.12% of their US portfolio. Moreover, Opus Point Partners Management Llc has 0.2% invested in the company for 25,231 shares. The New York-based Kingdon Capital Management L.L.C. has invested 0.16% in the stock. Cadence Capital Management Llc, a Massachusetts-based fund reported 180,715 shares.

Investors sentiment increased to 1.4 in Q4 2017. Its up 0.29, from 1.11 in 2017Q3. It improved, as 32 investors sold OSI Systems, Inc. shares while 41 reduced holdings. 43 funds opened positions while 59 raised stakes. 18.13 million shares or 1.07% more from 17.94 million shares in 2017Q3 were reported. Savings Bank Of America De accumulated 130,214 shares. Barclays Public Limited Liability Company reported 10,885 shares stake. Louisiana State Employees Retirement Sys, a Louisiana-based fund reported 7,700 shares. 85,973 were accumulated by Emerald Mutual Fund Advisers. Ny State Common Retirement Fund has invested 0.02% in OSI Systems, Inc. (NASDAQ:OSIS). Goldman Sachs Grp Inc Inc has 123,393 shares for 0% of their portfolio. Morgan Stanley has invested 0% in OSI Systems, Inc. (NASDAQ:OSIS). Moreover, Gotham Asset Mgmt Lc has 0.01% invested in OSI Systems, Inc. (NASDAQ:OSIS). Moreover, Granahan Mgmt Incorporated Ma has 1.28% invested in OSI Systems, Inc. (NASDAQ:OSIS). California Public Employees Retirement System reported 0% stake. Moreover, American Century has 0.02% invested in OSI Systems, Inc. (NASDAQ:OSIS). Victory Capital Mngmt accumulated 2,806 shares. Css Ltd Company Il invested in 0% or 1,028 shares. 6,902 were accumulated by Martingale Asset Management Ltd Partnership. Millennium Mgmt Ltd Company, a New York-based fund reported 426,163 shares.

Analysts await OSI Systems, Inc. (NASDAQ:OSIS) to report earnings on April, 25. They expect $0.83 EPS, down 2.35% or $0.02 from last year’s $0.85 per share. OSIS’s profit will be $15.79M for 20.43 P/E if the $0.83 EPS becomes a reality. After $0.97 actual EPS reported by OSI Systems, Inc. for the previous quarter, Wall Street now forecasts -14.43% negative EPS growth.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart